DE60033062T2 - Antikörper spezifisch für dendritische zellen, zusammensetzungen und verfahren, die diese antikörper verwenden, das durch die antikörper detektierte antigen und die dadurch erhaltenen zellen - Google Patents

Antikörper spezifisch für dendritische zellen, zusammensetzungen und verfahren, die diese antikörper verwenden, das durch die antikörper detektierte antigen und die dadurch erhaltenen zellen Download PDF

Info

Publication number
DE60033062T2
DE60033062T2 DE60033062T DE60033062T DE60033062T2 DE 60033062 T2 DE60033062 T2 DE 60033062T2 DE 60033062 T DE60033062 T DE 60033062T DE 60033062 T DE60033062 T DE 60033062T DE 60033062 T2 DE60033062 T2 DE 60033062T2
Authority
DE
Germany
Prior art keywords
bdca
antigen
cells
cell
mab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60033062T
Other languages
German (de)
English (en)
Other versions
DE60033062D1 (de
Inventor
Juergen Schmitz
Andrzej Dzionek
William David Mayfield BUCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Miltenyi Biotec GmbH
Original Assignee
Miltenyi Biotec GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27558547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60033062(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Miltenyi Biotec GmbH filed Critical Miltenyi Biotec GmbH
Publication of DE60033062D1 publication Critical patent/DE60033062D1/de
Application granted granted Critical
Publication of DE60033062T2 publication Critical patent/DE60033062T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
DE60033062T 1999-11-15 2000-11-15 Antikörper spezifisch für dendritische zellen, zusammensetzungen und verfahren, die diese antikörper verwenden, das durch die antikörper detektierte antigen und die dadurch erhaltenen zellen Expired - Lifetime DE60033062T2 (de)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US16555599P 1999-11-15 1999-11-15
US165555P 1999-11-15
US16707699P 1999-11-23 1999-11-23
US167076P 1999-11-23
US17900300P 2000-01-28 2000-01-28
US179003P 2000-01-28
US18077500P 2000-02-07 2000-02-07
US180775P 2000-02-07
US19682400P 2000-04-11 2000-04-11
US196824P 2000-04-11
US19720500P 2000-04-13 2000-04-13
US197205P 2000-04-13
PCT/IB2000/001832 WO2001036487A2 (en) 1999-11-15 2000-11-15 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby

Publications (2)

Publication Number Publication Date
DE60033062D1 DE60033062D1 (de) 2007-03-08
DE60033062T2 true DE60033062T2 (de) 2007-08-23

Family

ID=27558547

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60033062T Expired - Lifetime DE60033062T2 (de) 1999-11-15 2000-11-15 Antikörper spezifisch für dendritische zellen, zusammensetzungen und verfahren, die diese antikörper verwenden, das durch die antikörper detektierte antigen und die dadurch erhaltenen zellen

Country Status (11)

Country Link
EP (3) EP1783141A1 (enExample)
JP (4) JP5007007B2 (enExample)
KR (1) KR100868235B1 (enExample)
CN (1) CN1454215B (enExample)
AU (1) AU785198B2 (enExample)
CA (2) CA2664137C (enExample)
DE (1) DE60033062T2 (enExample)
DK (1) DK1301539T3 (enExample)
ES (1) ES2280264T3 (enExample)
PT (1) PT1301539E (enExample)
WO (1) WO2001036487A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1783141A1 (en) * 1999-11-15 2007-05-09 Miltenyi Biotec GmbH Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
EP1351985A2 (en) * 2000-10-16 2003-10-15 Bayer Aktiengesellschaft Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors
US7252990B2 (en) 2001-03-12 2007-08-07 Lexicon Genetics Incorporated Human dectin proteins and polynucleotides encoding the same
EP1395826A4 (en) * 2001-05-17 2005-11-09 Miltenyi Biotec Gmbh ANTIGEN-BINDING FRAGMENTS FOR A SUB-GROUP OF DENDRITIC CELLS AND USE THEREOF
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
CA2582471A1 (en) * 2004-10-07 2006-04-13 Universitaet Zuerich Type i interferon blocking agents for prevention and treatment of psoriasis
KR101363120B1 (ko) 2005-02-10 2014-02-13 베일러 리서치 인스티튜트 항-인터페론 알파 모노클로날 항체 및 사용 방법
EP2279207B1 (en) 2008-05-07 2015-09-09 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
NZ593240A (en) * 2009-01-06 2013-01-25 Functional Genetics Inc Random homozygous gene perturbation (rhgp) with thermal assymetric interlaced (tail)-pcr
FR2968561B1 (fr) * 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
US20150238632A1 (en) * 2012-09-18 2015-08-27 University Of Washington Through Its Center For Commercialization Compositions and Methods for Delivery of Antigens to Plasmacytoid Dendritic Cells
MX363407B (es) * 2012-12-10 2019-03-22 Biogen Ma Inc Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.
AU2014365838B2 (en) 2013-12-16 2021-01-14 The University Of North Carolina At Chapel Hill Depletion of plasmacytoid dendritic cells
CN109535254B (zh) 2013-12-24 2022-06-24 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
US10993990B2 (en) * 2014-05-16 2021-05-04 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
WO2016038168A1 (en) * 2014-09-10 2016-03-17 Miltenyi Biotec Gmbh A cell population for use in treting cancer
CA2969402C (en) 2014-12-03 2019-06-11 Samsung Life Public Welfare Foundation Antibody binding to neuropilin 1 and use thereof
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
FR3045386B1 (fr) * 2015-12-16 2018-02-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation d'un anticorps dirige contre une proteine membranaire
RS62463B1 (sr) * 2016-10-21 2021-11-30 Inst Nat Sante Rech Med Postupci za unapređivanje odgovora t ćelija
FR3060394B1 (fr) * 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
FR3060395B1 (fr) * 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
JP7158642B2 (ja) * 2018-01-16 2022-10-24 国立大学法人山梨大学 質量分析装置及び質量分析システム
WO2020227595A1 (en) * 2019-05-09 2020-11-12 Atara Biotherapeutics, Inc. Clec4-targeted car-t-cells
IL303279A (en) * 2020-12-03 2023-07-01 Biogen Ma Inc Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus
CN114264825B (zh) * 2021-12-22 2023-08-15 重庆医科大学附属儿童医院 一种b淋巴细胞发育亚群免疫分型的方法和试剂盒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2190367A1 (en) * 1995-03-15 1996-09-19 Stefan Miltenyi Isolation of hematopoietic dendritic cells by high gradient magnetic cell sorting
US5871728A (en) * 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
HUP0002472A3 (en) * 1997-07-09 2003-08-28 Schering Corp Isolated dendritic cell membrane protein genes
FI973762A0 (fi) * 1997-09-23 1997-09-23 Krohn Kai Ny gen
CA2307014A1 (en) * 1997-10-28 1999-05-06 Immunex Corporation Viral encoded semaphorin protein receptor dna and polypeptides
JP2002506645A (ja) * 1998-03-17 2002-03-05 シェーリング コーポレイション 単離された哺乳動物膜タンパク質遺伝子および関連試薬
EP1783141A1 (en) * 1999-11-15 2007-05-09 Miltenyi Biotec GmbH Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby

Also Published As

Publication number Publication date
AU785198B2 (en) 2006-11-02
ES2280264T3 (es) 2007-09-16
CA2664137A1 (en) 2009-07-16
EP1783141A1 (en) 2007-05-09
AU1723301A (en) 2001-05-30
JP2008148700A (ja) 2008-07-03
DE60033062D1 (de) 2007-03-08
JP2011092210A (ja) 2011-05-12
JP5007007B2 (ja) 2012-08-22
WO2001036487A3 (en) 2002-05-10
JP2012152215A (ja) 2012-08-16
EP1813626B1 (en) 2015-02-18
EP1813626A1 (en) 2007-08-01
CN1454215B (zh) 2013-01-02
KR20030032904A (ko) 2003-04-26
EP1301539B1 (en) 2007-01-17
JP2004512006A (ja) 2004-04-22
JP5599834B2 (ja) 2014-10-01
WO2001036487A2 (en) 2001-05-25
DK1301539T3 (da) 2007-05-21
CA2396428C (en) 2014-03-11
CA2396428A1 (en) 2001-05-25
CA2664137C (en) 2012-09-25
PT1301539E (pt) 2007-04-30
EP1301539A2 (en) 2003-04-16
CN1454215A (zh) 2003-11-05
KR100868235B1 (ko) 2008-11-12
JP5355602B2 (ja) 2013-11-27

Similar Documents

Publication Publication Date Title
DE60033062T2 (de) Antikörper spezifisch für dendritische zellen, zusammensetzungen und verfahren, die diese antikörper verwenden, das durch die antikörper detektierte antigen und die dadurch erhaltenen zellen
US20200283499A1 (en) Use of an antibody specific for BDCA 2 for ligation and removal of dendritic cells in the treatment systemic lupus erythematosis
DE69233136T2 (de) Ein selectin ligand
KR100289201B1 (ko) 조혈 단백질과 그것의 제조를 위한 재료 및 방법
AU7378096A (en) Porcine cell interaction proteins
JPH08502242A (ja) 多重付着分子に対する特異性を有する抗体
DE69232427T2 (de) Suppressorzellen
DE69430846T2 (de) Für natürliche killerzellen spezifische antigene und sie identifizierende antikörper
US20030022249A1 (en) Antigen-binding fragments that recognize a subset of dendritic cells and methods of use thereof
CA2794123A1 (en) Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO1996015227A1 (en) Methods of inducing cell death of primitive hematopoietic cells and compositions for induction thereof
Sexton Characterization of SaBR, a novel murine cell surface protein
Down et al. Syngeneic and allogeneic bone marrow engraftment after total body
WO1998051345A2 (en) Method for dislodging infiltrated leukocytes from a tissue
EP0866807A1 (en) Porcine cell interaction proteins

Legal Events

Date Code Title Description
8364 No opposition during term of opposition